A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimulation (COS) Using a Minimal Stimulation Protocol.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs MVT 602 (Primary) ; Triptorelin
- Indications Anovulation; Female infertility
- Focus Pharmacodynamics
- Sponsors Myovant Sciences
- 08 Nov 2018 According to a Myovant Sciences media release, top-line results from the study are expected in the first half of 2019.
- 08 Nov 2018 Status changed from recruiting to active, no longer recruiting, according to a Myovant Sciences media release.
- 01 Jun 2018 New trial record